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Hypertension and Associated right Heart Failure: Breaking 
the Vicious Circle; and (4) PrEdiCt: Predict sudden Car-
diac death—Uncover novel Genes and mechanisms and 
test Hypotheses in the Clinic.
The main benefit of the CVON approach is bringing 
researchers in the same field together (from experimental to 
clinical) potentially leading to a better focus and improved 
reorientation in order to perform joint research at a higher 
level. The benefits of this synergetic strategy were also rec-
ognised outside the netherlands [1]. However, in 2014 it 
was felt that a potential drawback of the large programmes 
was that only a limited number of programmes could be 
supported, mainly directed by older established investiga-
tors, while CVon should also serve and stimulate young 
researchers [2].
To that purpose, the Heart Foundation found an adequate 
solution by funding smaller programmes for 1.0–1.5 mil-
lion € each. As a result, in January 2015 the following six 
programmes were supported by ISAC, consisting of three 
large programmes: (1) EnErGisE (metabolic activation to 
prevent cardiovascular disease), (2) RACE V (prevention of 
complications in atrial fibrillation), (3) RE-CONNECT (dia-
stolic heart failure in diminished kidney function), and three 
smaller programmes: (1) CONCOR-GENES (prediction of 
complications in congenital heart disease), (2) rEmAin 
(more effective treatment after myocardial infarction) and 
(3) dosis (new causative mechanisms in hereditary cardio-
vascular diseases). in total, the Heart Foundation invested 
19.5 million € in these six programmes. For an extensive 
description of the supported programmes see www.hart-
stichting.nl.
Altogether, the granted CVON programmes nicely fit 
within the recently determined research agenda of the Heart 
Foundation consisting of five themes: (1) early recogni-
tion of cardiovascular disease, (2) cardiovascular disease in 
in the year 2010, the netherlands Cardiovascular research 
Committee (CVon, www.cvon.eu) was installed based on 
an initiative of The Netherlands Heart Foundation (cur- 
rently heart foundation). At that time, funding of research 
by the Heart Foundation changed from a bottom-up 
approach to a top-down approach. the Heart Foundation 
was assisted by the following organisations: The Nether-
lands Federation of University Medical Centers (NFU), the 
Royal Netherlands Academy of Arts and Sciences (KNAW) 
and The Netherlands Organisation for Scientific Research 
(NWO/ZonMw).
In the spring of 2011, a call for nationwide proposals 
went out for the first time. Consequently, large, nationwide 
consortia were formed with the task to formulate integrated 
research proposals. All proposals were carefully reviewed 
by a dedicated International Scientific Advisory Council 
(ISAC) which decided in January 2102 to fund three pro-
grammes for a total of 3.0–5.0 million € each. The follow-
ing three large programmes were granted: a programme on 
regenerative medicine (HUSTCARE), one searching for 
new biomarkers and therapeutic targets for atherosclerosis 
(GENIUS), and finally a programme on the development of 
drugs for heart failure (ARENA).
Likewise, in 2012, the same policy was followed and 
a total of four programmes were supported in 2013: (1) 
1VALVE: One Valve for Life; (2) HBC: The Heart-Brain 
Connection: The Missing Link in the Pathophysiology of 
Vascular Cognitive impairment; (3) PHAEdrA: Pulmonary 
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women, (3) improved treatment of heart failure and atrial 
fibrillation [3], (4) acute treatment of cerebrovascular acci-
dents and (5) new ways of continuing a healthy lifestyle [4].
The Heart Foundation should be credited for taking the 
initiative of starting CVON and, more importantly, for hav-
ing continued this approach for several years. Many mil-
lions of Euros have been invested in scientific research with 
the aim to unite different research groups across the coun-
try both at the clinical and basic level. However, the final 
goal of the CVON programmes should stretch much further 
than just the formation of consortia. CVON should encour-
age young researchers, stimulate efforts in performing joint 
research and pay attention that the results are published in 
high-quality journals. But foremost, the scientific results 
have to be translated into benefits for the community. Ulti-
mately, it is the community that raised the money, making 
all these scientific efforts possible. Consequently, societal 
impact is ‘the heart of the matter’. Of course, this is an issue 
which can only be assessed in the long run. nevertheless it 
should be the ‘red wire’ in performing scientific research 
today. The time of ‘l’art pour l‘art’ in science has gone as 
was also emphasised recently by a group of Dutch scientists 
called science in transition [5].
Fortunately, the Heart Foundation-directed CVon pro-
grammes yield sufficient confidence that they will serve the 
community both in prevention and treatment of cardiovas-
cular disease.
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